Prenetics Global Limited (PRE)
NASDAQ: PRE · Real-Time Price · USD
18.43
+0.01 (0.05%)
Jan 26, 2026, 2:09 PM EST - Market open
Prenetics Global Revenue
Prenetics Global had revenue of $23.56M in the quarter ending September 30, 2025, with 202.84% growth. This brings the company's revenue in the last twelve months to $77.08M, up 201.54% year-over-year. In the year 2024, Prenetics Global had annual revenue of $30.62M with 40.83% growth.
Revenue (ttm)
$77.08M
Revenue Growth
+201.54%
P/S Ratio
3.16
Revenue / Employee
$270,453
Employees
285
Market Cap
310.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 30.62M | 8.88M | 40.83% |
| Dec 31, 2023 | 21.74M | 8.58M | 65.17% |
| Dec 31, 2022 | 13.16M | 631.26K | 5.04% |
| Dec 31, 2021 | 12.53M | -52.65M | -80.77% |
| Dec 31, 2020 | 65.18M | 55.95M | 605.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 825.30M |
| OPKO Health | 642.07M |
| CareDx | 358.00M |
| Fulgent Genetics | 315.55M |
| FONAR | 105.43M |
| MDxHealth | 103.07M |
| Biodesix | 80.17M |
| Burning Rock Biotech | 75.75M |
PRE News
- 5 days ago - Prenetics: Strong Liquidity And Rapidly Rising Revenue - Seeking Alpha
- 9 days ago - Prenetics Global: Is Undervalued, Supported By Portfolio Optimization In 2026 (Buy) - Seeking Alpha
- 26 days ago - Buying bitcoin is no longer a thing for this David Beckham-backed health company - Market Watch
- 4 weeks ago - Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure - GlobeNewsWire
- 2 months ago - Prenetics Announces Upcoming Conference Participation - GlobeNewsWire
- 2 months ago - Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million - GlobeNewsWire
- 2 months ago - Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth - GlobeNewsWire
- 2 months ago - Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History - GlobeNewsWire